The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1295
Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Clevidipine (Cleviprex – The Medicines Company), a dihydropyridine calcium channel blocker (CCB), has been approved by the FDA for intravenous (IV) use in lowering high blood pressure. It is the second IV CCB to be marketed in the US; nicardipine has been available in an IV formulation (Cardene IV) for more than 10 years. Like IV nicardipine, clevidipine will probably be used mainly for urgent treatment of hypertension in intensive care units, operating rooms and emergency departments.

DRUGS FOR HYPERTENSIVE EMERGENCIES — The usual goal of treatment for a hypertensive crisis is to reduce blood pressure quickly, while avoiding hypotension that could lead to myocardial infarction, stroke or loss of vision.1,2 Sodium nitroprusside, a short-acting arterial and venous dilator, was the treatment of choice for many years, but its toxicity (it is metabolized to cyanide) and ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Clevidipine (Cleviprex) for IV Treatment of Severe Hypertension
Article code: 1295a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian